Natulan (Procarbazine Hydrochloride)

Procarbazine Hydrochloride, the active ingredient in Natulan, is an alkylating agent presented as a oral formulation for oral use. It is employed in the treatment of Hodgkin's lymphoma and certain brain tumors in adult patients.

GNH USA supplies Natulan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Procarbazine Hydrochloride is an alkylating antineoplastic agent used in specific hematologic and solid‑tumor cancers.

- Hodgkin's lymphoma: incorporated into multi‑drug chemotherapy regimens to achieve remission. - Brain tumors: used in selected malignant brain‑tumor protocols to improve survival outcomes.

Procarbazine Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Loss of appetite: reduced desire to eat. - Mild leukopenia: slight decrease in white blood cells.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: profound pancytopenia requiring medical intervention. - Secondary malignancies: rare development of new cancers. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Seizures: uncommon neurologic events.

Careful monitoring and patient assessment are essential when using procarbazine.

- Monitor blood counts: regular CBC to detect myelosuppression. - Assess liver function: periodic liver enzyme tests are recommended. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Use caution in renal impairment: dose adjustment may be required. - Store at room temperature: keep in the original pack, protect from moisture.

Procarbazine can interact with several drug classes, affecting safety and efficacy.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crises. - Other myelosuppressive agents: combined use increases risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin): may alter procarbazine metabolism. - Oral contraceptives: efficacy may be reduced, requiring alternative contraception. - Warfarin: procarbazine can affect INR, necessitating closer monitoring.